Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF-mutated Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03430947
What this trial is testing

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Who this might be right for
Malignant Melanoma Stage IVBRAF V600 MutationBrain Metastases
Technische Universität Dresden 20
Testing effectiveness (Phase 2)Study completedNCT02392871
What this trial is testing

Radiotherapy & Combi in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited 10
Testing effectiveness (Phase 2)Ended earlyNCT04655157
What this trial is testing

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Who this might be right for
Melanoma
Jason J. Luke, MD 2
Large-scale testing (Phase 3)Study completedNCT01597908
What this trial is testing

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 704
Early research (Phase 1)Study completedNCT01673737
What this trial is testing

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Who this might be right for
Neoplasm Malignant
Sanofi 75
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Early research (Phase 1)WithdrawnNCT02068079
What this trial is testing

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Who this might be right for
Melanoma
Duke University
Not applicableStudy completedNCT05806268
What this trial is testing

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Who this might be right for
BRAF v600 Mutated Metastatic Melanoma
Novartis Pharmaceuticals 214
Testing effectiveness (Phase 2)Ended earlyNCT01562899
What this trial is testing

MEK162 and AMG 479 in Patients With Selected Solid Tumors

Who this might be right for
Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
Pfizer 77
Not applicableStudy completedNCT01990248
What this trial is testing

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 339
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Active Not RecruitingNCT02721459
What this trial is testing

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 26
Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Ended earlyNCT01754376
What this trial is testing

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Study completedNCT02537600
What this trial is testing

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

Who this might be right for
Malignant Melanoma
Center Eugene Marquis 43
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Not applicableStudy completedNCT02310451
What this trial is testing

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Nice 15
Early research (Phase 1)Study completedNCT01264380
What this trial is testing

The Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 16
Next Page